NCT06481553View on ClinicalTrials.gov

RWS of Paclitaxel Liposome Combined With Anti-HER-2 Monoclonal Antibody

Active, not recruitingOBSERVATIONAL
Enrollment

480

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

July 31, 2024

Conditions
Breast Cancer Stage IV
Interventions
DRUG

first line treatment

Paclitaxel liposome in combination with trastuzumab (or trastuzumab biosimilar, or pyrotinib) ± pertuzumab ± other chemotherapy drugs (such as capecitabine, carboplatin, gemcitabine) may be used for HER-2 positive patients, with the addition of endocrine therapy for triple-positive patients.

Trial Locations (1)

100021

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER